Andros Pharmaceuticals announced on the 30th that its new drug, APC201, for treating knee osteoarthritis is progressing smoothly in its Phase II clinical trial in Australia. The company has already enrolled over 85% of participants, with the goal of completing the full enrollment by the end of this year. Preliminary data is expected to be available in the first quarter of next year. Based on these results, Andros plans to initiate a global multi-center Phase III clinical trial and explore international licensing and collaboration opportunities.
The company noted that the highest concentration and most effective nonsteroidal anti-inflammatory drug (NSAID) currently approved in the United States for treating osteoarthritis is Diclofenac 2% solution. This product, which has the highest concentration and market share among similar products in the U.S., generates annual sales exceeding one billion dollars. However, the solution form is prone to dripping and is expensive. It also contains the highly absorbent organic solvent dimethyl sulfoxide (DMSO), which can cause irritation. In clinical trials, approximately 65% of patients experienced increased tightness and discomfort at the application site due to the need for application twice or four times a day.
APC201, designed with a dual-effect lipid patent formula, effectively increases the drug concentration to 4% and reduces the application frequency to once per day. It does not contain irritating solvents, preventing skin irritation, significantly improving absorption, and reducing side effects. Additionally, APC201 comes in a foam form, which prevents dripping when applied to the knee, increasing patient compliance and convenience. If approved for market use, APC201 could provide patients with a new treatment option and tap into the substantial osteoarthritis pain market.
The Phase II clinical trial in Australia is nearing completion, with 85% of the target enrollment achieved. The trial is expected to be finished by the end of the year, followed by statistical analysis and data review. Preliminary results will be available in the first quarter of next year, and Andros plans to use this data to design a global multi-center Phase III trial. The company will also seek international licensing and collaboration opportunities to secure royalties and milestone payments, aiming to unlock the economic value of the drug and demonstrate operational success.
Resource (mandarin): 竟天APC201年底完成二期臨床收案 明年規劃三期並啟動授權合作
